Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints

Ashish Dubey (PM/2023/405) & Sai Deepika (PM/2023/419)

Guided by Dr. B Lakshmi & Mr. Sai Kishore V

Department of Pharmaceutical Management- National Institute of Pharmaceutical Education and Research – Hyderabad

Abstract

Although the pharmaceutical business is a major force in the advancement of healthcare, questions continue to be raised about the moral limits of medication marketing strategies, especially when it comes to off-label promotion. This review study sheds light on the tactics and procedures used in pharmaceutical off-label marketing by undertaking a thorough retrospective analysis of whistleblower allegations. We investigate the many facets of off-label promotion, looking at the techniques, goals, and outcomes by combining data from industry practises, legal cases, and regulatory actions.

Apart from analysing the adverse effects linked to off-label marketing, this assessment pinpoints possible domains for enhancement in regulatory structures and enforcement protocols. Our objective is to offer valuable insights that can guide the formulation of future policies and industry practises by critically evaluating past cases. In the end, this research adds to the continuing conversation on the moral issues raised by pharmaceutical marketing and the necessity of finding a balance between patient welfare, innovation, and regulatory compliance in the rapidly changing healthcare environment.

Key words: *Off-label marketing, Whistleblower, retrospective analysis*

Introduction

Regulatory agencies allow "labelled" applications of prescription drugs after determining their safety and efficacy based on preclinical and clinical research (Alexander, 2005b), however, medications are recommended off-label without going through stringent regulations. Marketing approval requires completing the approval process (Gupta & Nayak, 2014).Companies are not allowed to promote medications off-label, for an unapproved use, or in an unapproved form, dose, or strength, according to EU legislation. The fundamental justification for prohibiting off-label advertising is the potential for significant patient hazards and unwarranted costs to the healthcare system associated with promoting medications whose efficacy and safety have not been established**.**(Vilhelmsson et al., 2016). The US Food and Drug Administration (FDA) has permitted direct-to-consumer (DTC) pharmaceutical advertising since 1985 (Kesselheim, 2011a). While detractors contend that DTC advertising erodes the patient-physician relationship, supporters contend that it gives patients useful information and gives them the power to make medical decisions, and connections, which results in improper prescription procedures, and raises the cost of healthcare(Klara et al., 2018). However, the occurrence of off-label use is not limited to a single country or to extremely specialized clinical conditions. Off-label use is a global issue with similar dimensions published in North America and several European nations(Kazis et al., 2019b). In all drug classes are implicated, kids. Not even roughly 60% of Essential countermeasures for poisoning treatments must be given off-label medication in kids(Boos, 2003).Since off-label marketing operations are clandestine and challenging to identify and investigate through alternative channels, insider reports offer a distinctively revealing viewpoint on the variety and character of tactics used(*"Off-Label" Use of Prescription Drugs: Legal, Clinical and Policy Considerations*, 1997).

Ninety percent of healthcare fraud prosecutions at this time are "qui tam" cases, meaning that the government files the lawsuit on behalf of whistleblowers who have firsthand knowledge of the alleged fraud. 5 Qui tam comes from the Latin qui tam pro domino rege quam pro se ipso in hac parte sequitur, which translates as "who sues in this issue as well for the king as for himself." A share of the reward could be obtained by the whistleblower if a qui tam action results in a cash recovery(Kesselheim et al., 2010).

Whistleblower Complaints in the Pharmaceutical Industry

The pharmaceutical industry's whistleblower allegations have been instrumental in bringing illegal and unethical behavior to light (Kimland & Odlind, 2012). This review article's subtopic delves into the importance, workings, and results of whistleblower complaints in the pharmaceutical industry (Mostaghim et al., 2017). It emphasizes how people who come forward with reports of wrongdoing act as defenders of patient safety and industry integrity(Mulinari, 2016).

The Importance of Reports from Whistleblowers

Exposing Misconduct- The utilization of whistleblower complaints is a crucial mechanism in detecting several sorts of misconduct within the pharmaceutical sector(Conroy & McIntyre, 2005). Due to these concerns, behaviors that may have stayed undiscovered, like off-label marketing, fake research, and misleading marketing strategies, have come to light(Casali, 2007).

Preserving Public Health and Patients Whistleblowers frequently reveal activities that endanger public health and patient safety. (A, 2016a)

Role of Whistleblowers

Often, the crime that someone wants to report is actually being perpetrated within their company, possibly by a senior officer.

1. Find and reveal misconduct. Whistleblowers frequently sound the first alarm when they discover misconduct within their company(Kazis et al., 2019b). They might also learn about unethical actions like harassment or discrimination. Whistleblowers contribute to the exposure of these problems and the punishment of wrongdoers by speaking out and disclosing their concerns(Valverde, 2012).

2. Guard the general welfare. Whistleblowing can aid in shielding the general population from danger. Whistleblowers have revealed financial wrongdoing, hazardous products, and environmental risks, for instance. Whistleblowers can help to stop harm and create a more just and safe society by revealing wrongdoing.(Kesselheim et al., 2010)

3. Encourage accountability and openness. Inside organisations, whistleblowing can support the development of accountability and openness. The signal that misconduct will not be accepted is sent when whistleblowers come forward. Additionally, it compels businesses to reevaluate their rules and practises and take action to stop misconduct in the future(Greenwood, 2011).

4. Encourage others to take a stand. Whistleblowers have the power to encourage others to expose misconduct(*AMERICAN ACADEMY OF PEDIATRICS Uses of Drugs Not Described in the Package Insert (Off-Label Uses) OFF-LABEL USE OF APPROVED DRUGS*, 2002). When individuals witness successful whistleblowers uncovering misconduct and bringing about constructive change. This may have a cascading effect that results in a society that is more moral and equitable (Alexander, 2005a)

Whistleblowers in the pharmaceutical industry are essential to maintaining public safety and health. They frequently sound the alarm when there is misconduct in the pharmaceutical industry, such as falsifying data from clinical trials, advertising medications for usage not authorized, and paying physicians to recommend medications, Drugs' advantages are overstated while their hazards are minimized. (Alexander, 2005b)

Legal Frameworks

Whistleblowing is now widely defined by legislation to cover disclosures regarding a variety of wrongdoings, including unlawful activities, dangerous situations, and unethical behavior (Avid & Oldberg, 2006). This guarantees whistleblowers protection even in the event that they provide wrongdoing details that aren't specifically protected by the law(Halabi, 2018). The legal structure that controls the use of off-label medications differs from nation to nation. Because the FDA does not control medical practice in the US, doctors are free to prescribe medications for purposes other than those listed on the label. Discussions over the morality and legality of off-label prescribing have arisen as a result of this legal disparity (Mannion & Davies, 2015a)

Strategies used in Off-labelled marketing

Pharmacies may find it hazardous to engage in off-label marketing. The FDA may impose heavy fines and penalties on a business that markets a medication for off-label usage. Off-label marketing, however, has the potential to boost earnings and a drug's market share, so there are significant potential benefits as well(Kesselheim, 2011a). It is unreasonable to expect pharmaceutical corporations to monitor sales representatives' off-label promotion since it generates revenue for both the businesses and the representatives.(Fugh-Berman & Melnick, 2008).

Pharmaceutical businesses market their products for off-label usage using a range of tactics. Among the most popular tactics are:

- Direct marketing to doctors: This includes mailing them promotional materials like pamphlets and journal articles, as well as sending sales personnel to their offices to discuss off-label uses of medications(Mulinari et al., 2021).
- Pharmaceutical firms frequently support medical conferences and symposiums where speakers address the usage of medications off-label(Kesselheim & Studdert, 2008)
- Research funding: Drug firms have the option to provide funding for studies on off-label usage of their products, with the results published in medical journals (Cras et al., 2007).
- Direct-to-consumer advertising: Pharmaceutical companies are permitted to directly advertise off-label applications of their drugs to consumers in certain countries(Boos, 2003b).

Motives behind Off-Label Drug Usage

Off-label drug use happens for a number of reasons, such as the following:

a. Restricted therapy options: When a patient's approved options are reached, medical professionals may look into off-label alternatives.

b. Emerging clinical evidence: New studies may show a medication is effective for a condition for which it was not originally licensed(Kesselheim, 2011b).

c. Tailored patient care: Doctors can customize a patient's treatment to meet their specific needs by using off-label medications.

d. Financial considerations: Off-label use of a less costly prescription may be favored in some circumstances over an approved drug(Dusdal & Powell, 2021)

Moral Connotations

Patient Safety: Off-label marketing may put patients' safety at risk by promoting medications for uses that don't meet the strict guidelines and safety checks needed for authorised indications. Unknowingly taking drugs with questionable effectiveness and perhaps dangerous side effects can happen to patients(Wang et al., 2017).

Knowledgeable Assent

It is the right of patients to make knowledgeable decisions regarding their medical care. Off-label marketing can make the process of informed consent more difficult if patients aren't aware of the possible hazards or off-label status of a medication. Concerns about patient autonomy and openness are brought up by this(Steinman et al., n.d.).

Interest-related conflicts

Pharmaceutical firms may have conflicts of interest when selling off-label applications because of their financial interest in promoting their medications. Financial incentives have the potential to sway healthcare providers' clinical judgement and make profit a higher priority than the health of their patients(Kazis et al., 2019a)

Legal Repercussions

Rules Regarding Off-Label Promotion

Strict rules prohibiting off-label promotion have been put in place by regulatory bodies including the FDA in the US. Pharmacies are not allowed to promote pharmaceuticals for purposes that the FDA has not approved according to the Food, Drug, and Cosmetic Act. Legal repercussions, such as fines and other penalties, may follow violations of these regulations(Ballon & Feifel, 2006).

Legal Repercussions for Drug Manufacturers

The legal repercussions of off-label marketing have been illustrated by a number of well-known cases in the pharmaceutical sector. A record-breaking $2.3 billion settlement in the United States v. Pfizer case, for instance, brought attention to the possible financial consequences of off-label marketing(Mckean & Monasterio, n.d.).

Whistleblower Actions

The discovery of off-label marketing tactics has been mostly attributed to whistleblower efforts. People who have firsthand knowledge of a pharmaceutical company's illicit promotion may sue the corporation under the False Claims Act, which might result in large financial settlements and penalties for the business(Long & Watts, 2013).

Violations of FDA Regulations

Unauthorized promotion of drug uses constitutes a primary avenue through which off-label marketing violates FDA regulations, as emphasized in studies (Heumann et al., 2013). FDA approval for specific uses involves rigorous clinical testing and safety assessments of drugs. Pharmaceutical companies are mandated to promote their medications to healthcare professionals and the public based on these approved uses. Contravening FDA regulations, even with some clinical support, occurs when a drug is promoted for off-label applications (Barbos et al., 2023).

Pharmacies involved in off-label marketing may face legal consequences under FDA laws, with penalties encompassing substantial fines, civil settlements, and lawsuits filed under the False Claims Act. Noteworthy cases, such as United States v. Pfizer Inc, underscore the considerable financial penalties that pharmaceutical companies may incur for employing off-label marketing tactics (Skiba, n.d.), drawing attention to potential legal consequences. Off-label marketing by pharmaceutical corporations has the potential to disseminate inaccurate or incomplete information about a drug's safety and effectiveness for unapproved usage. Fabricating scientific data to support off-label applications may result in FDA infractions and legal repercussions (Mintzes, 2018).

Patient Safety Concerns

A significant concern regarding patient safety in the context of off-label marketing is the lack of comprehensive testing for uses of prescription drugs that are not officially authorized. The utilization of medications off-label means that patients may be subjected to treatments that have not undergone the same level of clinical scrutiny as those approved by the FDA (Rich, 2012). This situation introduces the potential for patients to face unexpected side effects, raising uncertainties about the safety and effectiveness of such medications. Individuals who take drugs off-label are exposed to the risk of encountering unforeseen adverse effects that may not have been

thoroughly studied or documented. When a medication is used for unapproved purposes, its safety profile may deviate, placing patients' health in jeopardy of unexpected adverse reactions (Bi, 2015).

Whistleblower's Perspective

A strong sense of ethical obligation and a dedication to patient safety are frequently the driving forces behind whistleblowers who reveal off-label marketing tactics (Emmerich et al., 2012). Their choice to come forward is motivated by their desire to correct the situation, safeguard the public, and maintain the integrity of the pharmaceutical sector after witnessing actions that endanger patients(A, 2016b). It is not a decision that is made lightly to expose off-label marketing. Whistleblowers frequently compare the moral obligation to expose wrongdoing versus the possible personal and professional dangers. Maintaining a culture of honesty and safeguarding patient welfare requires acknowledging the critical role that whistleblowers play in preserving ethical norms(McKean & Monasterio, 2014)

FDA Actions and Enforcement

Pharmaceutical companies are prohibited by the FDA from directly promoting unapproved uses of drugs. This restriction is in place because such marketing could result in the widespread adoption of a drug without evidence of its efficacy and safety, exposing patients to uncertain benefits and potential adverse effects. Moreover, it may diminish incentives for manufacturers to conduct the necessary clinical trials to obtain FDA approval for new uses (Kesselheim et al., 2011). Congress could potentially empower the FDA to mandate manufacturers to conduct safety and efficacy trials for products with off-label uses exceeding a specific threshold. Given that physicians are not required to specify the intended use when prescribing a drug, alternative means might be employed to monitor the extent of off-label drug use (FDA POLICY Off-Label Drug Information Regulation, Distribution, Evaluation, and Related Controversies, 2009).

FDA regulations are designed to ensure that advertising and promotional practices are grounded in evidence from clinical experience and are truthful, balanced, and not misleading. The guidelines for pharmaceutical promotion are outlined in 21 Code of Federal Regulations (CFR) 202.1, covering advertisements in various media such as journals, newspapers, magazines, as well as radio, television, and telephone broadcasts (FDA POLICY Off-Label Drug Information Regulation, Distribution, Evaluation, and Related Controversies, 2009).

Regulatory Response

Early patient access to new innovative drugs is a fundamental social demand worldwide. Regulatory authorities and pharmaceutical industries collaborate to achieve early patient access through the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) frameworks for global development (*Regulating Off-Label Drug Use*, n.d.)

The UK self-regulatory authority is capable of dealing relatively quickly with instances of off-label promotion with high visibility such as advertising. However, relative to the US government-led approach, our study provides evidence of the limited capacity of the UK’s self-regulatory arrangements to uncover complex marketing campaigns that remain concealed from company outsiders (Vilhelmsson et al., 2016).If states do not find ways to increase their administrative regulatory capacities in regard to the negotiation, implementation, and ongoing management of PTAs, these PTAs will potentially drive greater health inequities (Walls et al., 2015).

Changes In Pharmaceutical Marketing Practices

According to the complaints, manufacturers aimed to increase the use of their products through off-label marketing schemes in three non–mutually exclusive ways. They sought to expand uses to different disease entities, to variations on the approved indication, and to alternatives to the approved dosing schedule(Kesselheim et al., 2011b).

collecting safety label changes for approved drugs Labelling changes for prescription drugs are categorized and published by the FDA on a monthly basis

The increase in safety label changes we identified points to the importance of active safety surveillance of all drugs after approval and in particular drugs approved through expedited development or review pathways(Mostaghim et al., 2017).

Impact On Healthcare Providers

The widespread practice of off-label marketing within the healthcare system encompasses behaviors and strategies that may resist external regulatory interventions. Our research findings indicate that a regulatory strategy cannot be considered complete and effective without physicians actively acting as a defense against off-label promotion (Kesselheim et al., 2011c). Many healthcare practitioners' express concerns about off-label marketing, particularly its negative impact on the quality of care and patient safety. Such concerns signify healthcare practitioners as genuine advocates and safety guardians for their patients (Al Omar et al., 2019).

Enhancing accountability is crucial in identifying instances of misconduct, fraud, or unethical behavior in healthcare organizations (A Hemorrhage of Off-Label Use, 2011). This heightened accountability fosters a sense of responsibility among healthcare providers. Furthermore, the analysis may serve as a catalyst for healthcare providers to strengthen whistleblower protection programs and mechanisms, thereby promoting transparency (Alexander, 2005c).

Quality improvement is another notable outcome, as addressing issues raised in whistleblower complaints can lead to enhancements in the quality of healthcare services, patient safety, and overall patient care. The various health plans in which individuals are enrolled provide comprehensive insurance coverage for physicians, hospitals, and prescription drug services (Kazis et al., 2019b).

The Role of Transparency

Employees, medical professionals, and other stakeholders feel empowered to expose malfeasance when pharmaceutical businesses are transparent (Loder & Biondi, n.d.). Investigations and corrective measures to shield patients from potentially dangerous off-label drug uses can result from whistleblower revelations. Transparency is fundamentally based on this commitment to patient welfare(Mannion & Davies, 2015b).

In the pharmaceutical sector, whistleblower reports of off-label marketing malfeasance are made possible and supported by transparency. Transparency in the workplace fosters moral behaviour and encourages staff members to voice issues, which ultimately protects patient safety and preserves the integrity of the industry(Klasmeier & Redish, 2011). Understanding how important transparency is is crucial to creating a culture where people feel confident enough to report wrongdoing and support the highest moral standards in off-label marketing.

METHODOLOGY

The literature search was limited to articles published from 2000 - 2023. The search for articles was done online by using the search words '' Strategies and practices in off-label marketing of pharmaceuticals:

a retrospective analysis of whistleblower complaints' in the title and keywords in research databases at Wiley, Elsevier, Taylor & Francis, ERIC, Springer, SAGE, Frontiers.

Analysis

The method used is the Preferred Reporting Item for Systemic Reviews and Meta analytic (PRISMA) method. All articles that have passed the selection process were then reviewed and summarised based on the objectives, year of publication, number of citations and suggestions for further research.

Inclusion & Exclusion criteria

The be included in current study, studies have to meet some criteria

(a) Studies have included some kind of selection criteria. These criteria limited the number of studies

(b) Accordingly excluded the studies in which it based on irrelevant information there is no proper Title, Abstract & Review.

Final data set

The research database search resulted in all keywords search results obtained 3000 research articles. After scanning the title, there was the same article in two different databases. The results after deducting the duplicates are 2300 articles. A total of 700 articles were screened. 500 Articles excluded that they not meet the inclusion criteria.

Articles accessed for eligibility are 120 articles. A Total number of articles excluded based on title and abstract (30) Irrelevant to topic (10) Duplicate (12).

The final data set consists of 57 articles.

The oldest included study was published in the year 2005 and the most recent study was conducted on 2021. The Entire process is shown in figure

PRISMA Flow Diagram



Discussion

The off-label marketing of medications involves a complicated interplay of tactics and practises, as revealed by the retrospective examination of whistleblower accusations. The patterns found in this research offer regulators a road map, encouraging them to review current frameworks and consider novel strategies for putting a stop to harmful practises. Ensuring the integrity of the pharmaceutical sector and protecting public health requires strict enforcement combined with a sophisticated grasp of changing marketing strategies. The conversation also emphasises the mutually beneficial relationship that exists between efficient regulation and whistleblowers. The importance of improved whistleblower protection programmes is shown by the priceless contributions made by individuals who reveal off-label marketing practises. In order to cultivate an ethical marketing culture and promote transparency, regulatory bodies must work in tandem with industry stakeholders to manage the fine line between supporting innovation and guaranteeing patient safety. This conversation acts as a springboard for continued discourse, advocating for coordinated efforts to tackle the problems associated with off-label marketing and strengthen the underpinnings of an ethical and patient-centered pharmaceutical environment.

Conclusion

To sum up, this retrospective examination of whistleblower complaints offers insightful information about the tactics and procedures used in pharmaceutical off-label marketing. The review has shed light on the intricate world of off-label promotion, exposing cases in which businesses have deviated from allowed uses, raising issues with patient safety and healthcare expenditures as well as potential legal ramifications.Whistleblowers' crucial role in exposing these practises is revealed, underscoring both their bravery and the difficulties they encounter in raising awareness of these problems. The review emphasises how crucial it is to preserve the integrity of the healthcare system by highlighting the necessity of a strong regulatory framework to stop off-label marketing. It is clear that a careful balance must be maintained between promoting innovation in the pharmaceutical business and ensuring patient safety when we consider past events and their ramifications. The evaluation advocates for a proactive strategy to addressing off-label marketing practises by suggesting potential areas for improvement in regulatory supervision and enforcement procedures.

This review seeks to influence future legislation and encourage ethical business practises by adding to the continuing conversation about the moral issues underlying pharmaceutical marketing. The retrospective study ultimately functions as a rallying cry for interested parties to work together to make sure that medical advancements in pharmaceuticals are in line with the strictest requirements for patient safety and legal compliance.

Referance

1. A, B. O. (2016a). EVALUATION OF DISINTEGRANT PROPERTIES OF Neorautanenia mitis STARCH. In *Journal of Phytomedicine and Therapeutic* (Vol. 15, Issue 2). www.jopat.gov.ng
2. A, B. O. (2016b). EVALUATION OF DISINTEGRANT PROPERTIES OF Neorautanenia mitis STARCH. In *Journal of Phytomedicine and Therapeutic* (Vol. 15, Issue 2). www.jopat.gov.ng
3. *A Hemorrhage of Off-Label Use*. (2011). http://annualreport2010.no-
4. Al Omar, M., Salam, M., & Al-Surimi, K. (2019). Workplace bullying and its impact on the quality of healthcare and patient safety. *Human Resources for Health*, *17*(1). https://doi.org/10.1186/s12960-019-0433-x
5. Alexander, R. (2005a). The role of whistleblowers in the fight against economic crime. In *Journal of Financial Crime* (Vol. 12, Issue 2, pp. 131–138). https://doi.org/10.1108/13590790510624945
6. Alexander, R. (2005b). The role of whistleblowers in the fight against economic crime. In *Journal of Financial Crime* (Vol. 12, Issue 2, pp. 131–138). https://doi.org/10.1108/13590790510624945
7. Alexander, R. (2005c). The role of whistleblowers in the fight against economic crime. In *Journal of Financial Crime* (Vol. 12, Issue 2, pp. 131–138). https://doi.org/10.1108/13590790510624945
8. *AMERICAN ACADEMY OF PEDIATRICS Uses of Drugs Not Described in the Package Insert (Off-Label Uses) OFF-LABEL USE OF APPROVED DRUGS*. (2002). http://www.fda.gov/
9. Avid, D., & Oldberg, J. G. (2006). DERMATOLOGIC THERAPY Legal ramifications of off-label filler use. *Dermatologic Therapy*, *19*, 189–193.
10. Ballon, J. S., & Feifel, D. (2006). Ballon and Feifel 554. In *J Clin Psychiatry* (Vol. 67, Issue 4).

11. Barbos, V., Feciche, B., Bratosin, F., Bogdan, I., Negrean, R. A., Latcu, S., Croitor, A., Dema, V., Bardan, R., & Cumpanas, A. A. (2023). A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania. *Healthcare (Switzerland)*, *11*(6). https://doi.org/10.3390/healthcare11060812
12. Bi, K. (2015). What Is "False or Misleading" Off-Label Promotion? In *Law Review* (Vol. 82, Issue 2). http://www.jstor.orgURL:http://www.jstor.org/stable/43410708
13. Boos, J. (2003a). Off label use - Label of use? In *Annals of Oncology* (Vol. 14, Issue 1, pp. 1–5). https://doi.org/10.1093/annonc/mdg035
14. Boos, J. (2003b). Off label use - Label of use? In *Annals of Oncology* (Vol. 14, Issue 1, pp. 1–5). https://doi.org/10.1093/annonc/mdg035
15. Casali, P. G. (2007). The off-label use of drugs in oncology: A position paper by the European Society for Medical Oncology (ESMO). In *Annals of Oncology* (Vol. 18, Issue 12, pp. 1923–1925). https://doi.org/10.1093/annonc/mdm517
16. Conroy, S., & McIntyre, J. (2005). The use of unlicensed and off-label medicines in the neonate. In *Seminars in Fetal and Neonatal Medicine* (Vol. 10, Issue 2, pp. 115–122). W.B. Saunders Ltd. https://doi.org/10.1016/j.siny.2004.11.003
17. Cras, A., Conscience, M. A., Rajzbaum, G., Lillo-Le Louët, A., Lopez, N., Tersen, I., & Bezie, Y. (2007). Off-label prescribing in a French hospital. *Pharmacy World and Science*, *29*(2), 97–100. https://doi.org/10.1007/s11096-006-9064-0
18. Dusdal, J., & Powell, J. J. W. (2021). Benefits, Motivations, and Challenges of International Collaborative Research: A Sociology of Science Case Study. *Science and Public Policy*, *48*(2), 235–245. https://doi.org/10.1093/scipol/scab010
19. Emmerich, J., Dumarcet, N., & Lorence, A. (2012). France's New Framework for Regulating Off-Label Drug Use. *New England Journal of Medicine*, *367*(14), 1279–1281. https://doi.org/10.1056/nejmp1208347
20. *FDA POLICY Off-Label Drug Information Regulation, Distribution, Evaluation, and Related Controversies*. (2009).
21. Fugh-Berman, A., & Melnick, D. (2008). Off-label promotion, on-target sales. In *PLoS Medicine* (Vol. 5, Issue 10, pp. 1432–1435). https://doi.org/10.1371/journal.pmed.0050210
22. Greenwood, K. (2011). The Ban on "Off-Label" Pharmaceutical Promotion: Constitutionally Permissible Prophylaxis Against False or Misleading Commercial Speech? In *American Journal of Law & Medicine* (Vol. 37). http://www.fda.gov/RegulatoryInformation/Guidances/ucm125126.htm.
23. Gupta, S. K., & Nayak, R. P. (2014). Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities. *Journal of Pharmacology and Pharmacotherapeutics*, *5*(2), 88–92. https://doi.org/10.4103/0976-500X.130046
24. Halabi, S. F. (2018). Off-label marketing's audiences: The 21st century cures act and the relaxation of standards for evidence-based therapeutic and cost-comparative claims. *American Journal of Law and Medicine*, *44*(2–3), 181–196. https://doi.org/10.1177/0098858818789420
25. Heumann, M., Friedes, A., Cassak, L., Wright, W., & Joshi, E. (2013). The World of Whistleblowing: From the Altruist to the Avenger. *Public Integrity*, *16*(1), 25–52. https://doi.org/10.2753/PIN1099-9922160102
26. Kazis, L. E., Ameli, O., Rothendler, J., Garrity, B., Cabral, H., McDonough, C., Carey, K., Stein, M., Sanghavi, D., Elton, D., Fritz, J., & Saper, R. (2019a). Observational retrospective study of the association of initial healthcare provider for new-onset low back pain with early and long-term opioid use. *BMJ Open*, *9*(9). https://doi.org/10.1136/bmjopen-2018-028633
27. Kazis, L. E., Ameli, O., Rothendler, J., Garrity, B., Cabral, H., McDonough, C., Carey, K., Stein, M., Sanghavi, D., Elton, D., Fritz, J., & Saper, R. (2019b). Observational retrospective study of the association of initial healthcare provider for new-onset low back pain with early and long-term opioid use. *BMJ Open*, *9*(9). https://doi.org/10.1136/bmjopen-2018-028633
28. Kesselheim, A. S. (2011a). Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech. In *American Journal of Law & Medicine* (Vol. 37). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm
29. Kesselheim, A. S. (2011b). Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech. In *American Journal of Law & Medicine* (Vol. 37). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm
30. Kesselheim, A. S., Mello, M. M., & Studdert, D. M. (2011a). Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. In *PLoS Medicine* (Vol. 8, Issue 4, p. 13). https://doi.org/10.1371/journal.pmed.1000431
31. Kesselheim, A. S., Mello, M. M., & Studdert, D. M. (2011b). Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. In *PLoS Medicine* (Vol. 8, Issue 4, p. 13). https://doi.org/10.1371/journal.pmed.1000431

32. Kesselheim, A. S., Mello, M. M., & Studdert, D. M. (2011c). Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. In *PLoS Medicine* (Vol. 8, Issue 4, p. 13). https://doi.org/10.1371/journal.pmed.1000431
33. Kesselheim, A. S., & Studdert, D. M. (2008). *Whistleblower-Initiated Enforcement Actions against Health Care Fraud and Abuse in the United States, 1996 to 2005 BACKGROUND: THE FALSE CLAIMS ACT AND QUI TAM ACTIONS*. https://annals.org/
34. Kesselheim, A. S., Studdert, D. M., & Mello, M. M. (2010). *Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies*.
35. Kimland, E., & Odlind, V. (2012). Off-label drug use in pediatric patients. In *Clinical Pharmacology and Therapeutics* (Vol. 91, Issue 5, pp. 796–801). https://doi.org/10.1038/clpt.2012.26
36. Klara, K., Kim, J., & Ross, J. S. (2018). Direct-to-consumer broadcast advertisements for pharmaceuticals: Off-label promotion and adherence to fda guidelines. *Journal of General Internal Medicine*, *33*(5), 651–658. https://doi.org/10.1007/s11606-017-4274-9
37. Klasmeier, C., & Redish, M. H. (2011). Off-Label Prescription Advertising, the FDA and the First Amendment: A Study in the Values of Commercial Speech Protection. In *American Journal of Law & Medicine* (Vol. 37).
38. Loder, E. W., & Biondi, D. M. (n.d.). *Research Submissions Off-Label Prescribing of Drugs in Specialty Headache Practice*.
39. Long, D., & Watts, C. (2013). Off-label use of drugs and devices: Role of medical professionals in the establishment of parameters for their use. *Neurosurgery*, *72*(6), 1014–1020. https://doi.org/10.1227/NEU.0b013e31828ba778
40. Mannion, R., & Davies, H. T. (2015a). Cultures of silence and cultures of voice: The role of whistleblowing in healthcare organisations. In *International Journal of Health Policy and Management* (Vol. 4, Issue 8, pp. 503–505). Kerman University of Medical Sciences. https://doi.org/10.15171/ijhpm.2015.120
41. Mannion, R., & Davies, H. T. (2015b). Cultures of silence and cultures of voice: The role of whistleblowing in healthcare organisations. In *International Journal of Health Policy and Management* (Vol. 4, Issue 8, pp. 503–505). Kerman University of Medical Sciences. https://doi.org/10.15171/ijhpm.2015.120
42. Mckean, A., & Monasterio, E. (n.d.). *Off-Label Use of Atypical Antipsychotics Cause for Concern?*
43. McKean, A., & Monasterio, E. (2014). Indications of atypical antipsychotics in the elderly. In *Expert Review of Clinical Pharmacology* (Vol. 8, Issue 1, pp. 5–7). Expert Reviews Ltd. https://doi.org/10.1586/17512433.2015.974557
44. Mintzes, B. (2018). The marketing of testosterone treatments for age-related low testosterone or "Low T." In *Current Opinion in Endocrinology, Diabetes and Obesity* (Vol. 25, Issue 3, pp. 224–230). Lippincott Williams and Wilkins. https://doi.org/10.1097/MED.0000000000000412
45. Mostaghim, S. R., Gagne, J. J., & Kesselheim, A. S. (2017). Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: Retrospective cohort study. *BMJ (Online)*, *358*. https://doi.org/10.1136/bmj.j3837
46. Mulinari, S. (2016). Unhealthy marketing of pharmaceutical products: An international public health concern. In *Journal of Public Health Policy* (Vol. 37, Issue 2, pp. 149–159). Palgrave Macmillan Ltd. https://doi.org/10.1057/jphp.2016.6
47. Mulinari, S., Davis, C., & Ozieranski, P. (2021). Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe. *Journal of White Collar and Corporate Crime*, *2*(2), 69–80. https://doi.org/10.1177/2631309x20970477
48. *"Off-label" use of prescription drugs: Legal, clinical and policy considerations*. (1997).
49. *Regulating Off-Label Drug Use*. (n.d.).
50. Rich, B. A. (2012). Off-label prescribing: In search of a reasonable patient-centered approach. In *Journal of Pain and Palliative Care Pharmacotherapy* (Vol. 26, Issue 2, pp. 131–133). https://doi.org/10.3109/15360288.2012.679335
51. Skiba, M. (n.d.). *How Controversial Pharmaceutical Marketing Practices Harm Stakeholders*.
52. Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S. (n.d.). *Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents*. www.annals.org
53. Valverde, J. L. (2012). Corporate responsibility and pharmaceutical fraud. *Pharmaceuticals Policy and Law*, *14*(2–4), 129–156. https://doi.org/10.3233/PPL-120350
54. Vilhelmsson, A., Davis, C., & Mulinari, S. (2016a). Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003–2012. *PLoS Medicine*, *13*(1). https://doi.org/10.1371/journal.pmed.1001945

55. Vilhelmsson, A., Davis, C., & Mulinari, S. (2016b). Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003–2012. *PLoS Medicine*, *13*(1). https://doi.org/10.1371/journal.pmed.1001945
56. Walls, H. L., Smith, R. D., & Drahos, P. (2015). Improving regulatory capacity to manage risks associated with trade agreements. In *Globalization and Health* (Vol. 11, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12992-015-0099-7
57. Wang, B., Studdert, D. M., Sarpatwari, A., Franklin, J. M., Landon, J., & Kesselheim, A. S. (2017). The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. *PLoS ONE*, *12*(4). https://doi.org/10.1371/journal.pone.0175313